These issues mirror the challenges seen with other markers of CKD-MBD such as PTH or phosphate measurements, but are unlikely to preclude the progressive integration of FGF-23 measurements into clinical practice. This evidence concerns the gene PTH and Marchiafava-Bignami disease.